Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 11/20 | 0.66 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3766399 | 0.88 | FAAH (0.67) | FAAHEPHX2TP53SMN1; SMN2MAPT | |
| SCHEMBL3772543 | 0.83 | L3MBTL1 (0.57) | FAAHEPHX2TP53SMN1; SMN2NAMPT | |
| SCHEMBL3764625 | 0.83 | FAAH (0.56) | FAAHEPHX2TP53MAPTNAMPT | |
| SCHEMBL3765745 | 0.83 | FAAH (0.61) | FAAHEPHX2TP53 | |
| SCHEMBL3640628 | 0.82 | FAAH (0.59) | FAAHEPHX2TP53SMN1; SMN2MAPT | |
| SCHEMBL3769604 | 0.80 | FAAH (0.58) | FAAHEPHX2 | |
| SCHEMBL3767561 | 0.80 | FAAH (1.00) | FAAHEPHX2TP53SMN1; SMN2 | |
| SCHEMBL3772085 | 0.79 | FAAH (0.57) | FAAHEPHX2 | |
| SCHEMBL3770680 | 0.79 | FAAH (0.56) | FAAHEPHX2TP53SMN1; SMN2MAPT | |
| SCHEMBL3768198 | 0.79 | FAAH (0.59) | FAAHEPHX2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851473-B2 | Amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-14 | — | — | US | disclosed |
| US-20080312226-A1 | Amide Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-1813606-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312226-A1 | Amide Compound | FAAH, FAAH2, CNR2 | FAAH 1/4885EPHX2 392/4885TP53 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.